Antibody response to Cryptococcus neoformans proteins in rodents and humans

被引:58
作者
Chen, LC
Goldman, DL
Doering, TL
Pirofski, LA
Casadevall, A
机构
[1] Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA
[2] Yeshiva Univ Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10461 USA
[3] Yeshiva Univ Albert Einstein Coll Med, Div Infect Dis, Dept Med, Bronx, NY 10461 USA
[4] Cornell Univ, Coll Med, Dept Pharmacol, New York, NY 10461 USA
关键词
D O I
10.1128/IAI.67.5.2218-2224.1999
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The prevalence and specificity of serum antibodies to Cryptococcus neoformans proteins was studied in mice and rats with experimental infection, in individuals with or without a history of potential laboratory exposure to C. neoformans, human immunodeficiency virus (HIV)-positive individuals who developed cryptococcosis, in matched samples from HIV-positive individuals who did not develop cryptococcosis, and in HIV-negative individuals. Rodents had little or no serum antibody reactive with C, neoformans proteins prior to infection. The intensity and specificity of the rodent antibody response were dependent on the species, the mouse strain, and the viability of the inoculum, All humans had serum antibodies reactive with C. neoformans proteins regardless of the potential exposure, the HIV infection status, or the subsequent development of cryptococcosis. Our results indicate (i) a high prevalence of antibodies reactive with C. neoformans proteins in the sera of rodents after cryptococcal infection and in humans with or without HIV infection; (ii) qualitative and quantitative differences in the antibody profiles of HN-positive individuals; and (iii) similarities and differences between humans, mice, and rats with respect to the specificity of the antibodies reactive,vith C, neoformans proteins. The results are consistent with the view that C, neoformans infections are common in human populations, and the results have implications for the development of vaccination strategies against cryptococcosis.
引用
收藏
页码:2218 / 2224
页数:7
相关论文
共 41 条
[1]  
ATKINSON AJ, 1968, AM REV RESPIR DIS, V97, P637
[2]  
BAKER RD, 1976, AM J CLIN PATHOL, V65, P83
[3]   SEROLOGY OF HUMAN CRYPTOCOCCOSIS [J].
BINDSCHADLER, DD ;
BENNETT, JE .
ANNALS OF INTERNAL MEDICINE, 1968, 69 (01) :45-+
[4]   ANTIBODY IMMUNITY AND INVASIVE FUNGAL-INFECTIONS [J].
CASADEVALL, A .
INFECTION AND IMMUNITY, 1995, 63 (11) :4211-4218
[5]  
CASADEVALL A, 1992, J INFECT DIS, V65, P1086
[6]  
CASDADEVALL A, 1998, MED MYCOL, V36, P95
[7]   RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISM ANALYSIS OF CRYPTOCOCCUS-NEOFORMANS ISOLATES FROM ENVIRONMENTAL (PIGEON EXCRETA) AND CLINICAL SOURCES IN NEW-YORK-CITY [J].
CURRIE, BP ;
FREUNDLICH, LF ;
CASADEVALL, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 1994, 32 (05) :1188-1192
[8]   Prospects for the development of fungal vaccines [J].
Deepe, GS .
CLINICAL MICROBIOLOGY REVIEWS, 1997, 10 (04) :585-&
[9]  
DESHAW M, 1995, CLIN EXP IMMUNOL, V99, P425, DOI 10.1111/j.1365-2249.1995.tb05568.x
[10]  
Devi Sarvamangala J. N., 1996, Immunology and Infectious Diseases (London), V6, P87